Thromboxane A2 receptor signalling amplifies osteoclastogenesis in rheumatoid arthritis through ACSL1 associated mitochondrial oxidative metabolism.

Thromboxane A2 receptor signalling enhances osteoclastogenesis and bone erosion in rheumatoid arthritis by increasing mitochondrial oxidative metabolism, involving ACSL1.

• Why it matters: Understanding how platelet-derived signals promote bone erosion in rheumatoid arthritis is crucial for developing targeted therapies, as the mechanisms remain poorly understood.
• What they did: The study used molecular analyses, pharmacological inhibition, and genetic deletion in mouse models to show that thromboxane A2 receptor signalling promotes osteoclast formation by boosting fatty acid oxidation and mitochondrial energy supply.
• The result: Receptor inhibition or deletion reduces osteoclast accumulation and bone destruction in male mice, suggesting thromboxane A2 signalling as a potential therapeutic target for inflammatory bone erosion.